张玉军++李宁+李晓景+宋军伟

[摘要] 目的 分析晚期食管癌患者实施带膜支架联合化疗的临床效果。 方法 从我院2012年5月～2014年3月收治的晚期食管癌患者中随机抽选实施化疗的30例作为对照组，实施带膜支架联合化疗的30例作为研究组，评定疾病治疗结束后的效果。 结果 研究组治疗后6个月、9个月、12个月的生存率分别为96.7%、86.7%、80.0%，对照组分别为80.0%、63.3%、53.3%，两组比较差异有统计学意义（P<0.05）。研究组并发症发生率为6.7%，对照组并发症发生率为26.7%，两组比较差异有统计学意义。 结论 临床给予晚期食管癌患者带膜支架联合化疗的治疗方法效果突出，可提高患者生存率，预防并发症，值得临床推广。

[关键词] 带膜支架；化疗；晚期食管癌；并发症

[中图分类号] R735.1 [文献标识码] B [文章编号] 1673-9701（2016）23-0082-03

[Abstract] Objective To evaluate the clinical effect of membrane-coated stent combined chemotherapy in the treatment of patients with advanced esophageal cancer. Methods 30 cases were randomly selected to receive chemotherapy from the patients with advanced esophageal cancer who were admitted in our hospital from May 2012 to March 2014 as the control group and 30 cases who were given membrane-coated stent combined chemotherapy were selected as the study group. The effect after treatment was evaluated. Results The survival rate of 6 months， 9 months and 12 months of the patients from the study group were respectively 96.7%， 86.7%and 80.0%， while that of the control group were 80.0%， 63.3% and 53.3%. The differences were statistically significant（P<0.05）. Conclusion The application of membrane-coated stent combined chemotherapy shows promising effect in the treatment of patients with advanced esophageal cancer， increases the survival rate and prevents complications， which deserves clinical recommendation.

[Key words] Membrane-coated stent； Chemotherapy； Advanced esophageal cancer； Complication

食管癌是临床上中老年常见的恶性肿瘤，其发病率较高[1]。患者常由于症状出现较晚，就诊时间过迟，自身体质差、肿瘤浸润范围过大或者经济等原因错过手术治疗的最佳时机，患者晚期不能进食，机体逐步衰竭，痛苦异常，消耗而终，严重危害生命健康[2]。目前，临床针对食管癌患者均实施放化疗，虽可有效控制病情的进一步恶化，但易引发胸痛、消化道出血等并发症，且远期生存率较低[3]。近年来，通过临床的不断探索[3-5]，发现对于晚期食管癌的患者，在化疗基础上联和应用带膜支架，操作安全、创伤小、见效快、并发症较少，能有效地解除狭窄、梗阻等问题，缓解吞咽困难症状，是一种患者可以接受的姑息治疗方法。为进一步评定该联合疗法的可行性，本文选择我院60例食管癌患者的资料，现报道如下。

1 资料与方法

1.1 一般资料

从我院2012年5月～2014年3月收治的晚期食管癌患者中随机选取实施化疗的30例作为对照组，其中男17例、女13例；……